COVID-19 vaccine immunogenicity in people with HIV
- DOI
- Language of the publication
- English
- Date
- 2023-01-01
- Type
- Article
- Author(s)
- Costiniuk, Cecilia T.
- Galipeau, Yannick
- Harris, Marianne
- Hull, Mark
- Brumme, Zabrina L.
- Lapointe, Hope R.
- Brockman, Mark A.
- Margolese, Shari
- Mandarino, Enrico
- Samarani, Suzanne
- Vulesevic, Branka
- Lebouché, Bertrand
- Angel, Jonathan B.
- Routy, Jean-Pierre
- Cooper, Curtis L.
- Anis, Aslam H.
- Lee, Terry
- Kovacs, Colin
- Jenabian, Mohammad-Ali
- Chambers, Catharine
- Brockman, Mark A.
- Samji, Hasina
- Burchell, Ann N.
- Ostrowski, Mario
- Tan, Darrell H. S.
- Walmsley, Sharon
- Singer, Joel
- Hull, Mark
- Brumme, Zabrina L.
- Lapointe, Hope R.
- Publisher
- Wolters Kluwer Health, Inc.
Abstract
OBJECTIVES: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Our objective was to compare COVID-19 vaccine immunogenicity in PWH to HIV-negative individuals. DESIGN: In a Canadian multi-center prospective, observational cohort of PWH receiving at least two COVID-19 vaccinations, we measured vaccine-induced immunity at 3 and 6 months post 2nd and 1-month post 3rd doses. METHODS: The primary outcome was the percentage of PWH mounting vaccine-induced immunity [co-positivity for anti-IgG against SARS-CoV2 Spike(S) and receptor-binding domain proteins] 6 months post 2nd dose. Univariable and multivariable logistic regressions were used to compare COVID-19-specific immune responses between groups and within subgroups. RESULTS: Data from 294 PWH and 267 controls were analyzed. Immunogenicity was achieved in over 90% at each time point in both groups. The proportions of participants achieving comparable anti-receptor-binding domain levels were similar between the group at each time point. Anti-S IgG levels were similar by group at month 3 post 2nd dose and 1-month post 3rd dose. A lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose [92% vs. 99%; odds ratio: 0.14 (95% confidence interval: 0.03, 0.80; P = 0.027)]. In multivariable analyses, neither age, immune non-response, multimorbidity, sex, vaccine type, or timing between doses were associated with reduced IgG response. CONCLUSION: Vaccine-induced IgG was elicited in the vast majority of PWH and was overall similar between groups. A slightly lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 months post 2nd dose demonstrating the importance of timely boosting in this population.
Subject
- Health
Keywords
- AIDS Vaccines*,
- Antibodies,
- COVID-19 Vaccines,
- COVID-19* / prevention & control,
- Canada,
- HIV Infections*,
- Humans,
- Immunogenicity, Vaccine,
- Prospective Studies,
- RNA, Viral,
- SARS-CoV-2
Rights
Pagination
F1-F10
Peer review
Yes
Open access level
Gold
Identifiers
- PubMed ID
- 36476452
- ISSN
- 1473-5571
Article
- Journal title
- AIDS
- Journal volume
- 37
- Journal issue
- 1
Sponsors
Supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force (grant number: 2122-HQ-000075), and the CTN (grant number: N/A). Production of COVID-19 reagents was financially supported by the National Research Council of Canada (NRC)'s Pandemic Response Challenge Program.